


Economic Indicators

CPI Inflation	Oct'20	8.9%
Current Account Balance	4MFY21	USD1.2bn
Remittances	4MFY21	USD9.4bn
SBP Reserves	13-Nov-20	USD12.9bn
6M KIBOR	23-Nov-20	7.1%
10 yr PIB	23-Nov-20	9.9%

Source: SBP, PBS, BIPLS Research

Reserves (USDmn)



Source: SBP, BIPLS Research

- In a widely anticipated move, SBP kept the benchmark interest rate stable at 7%.
- The central bank also reiterated its confidence in meeting the inflation target of 7% - 9% during FY21 and expect the supply side pressures to be gradually adjusted over the coming months.
- Real GDP growth target for the economy has been revised to a shade above 2% which is significantly higher than IMF's (1.0%) and WB's (1.3%) growth targets but in line with ours (1.9%).
- SBP was also appreciative of significant strides made towards improving the current account balance which currently stands at a surplus of USD1.2bn and expects FY21 to close with a deficit of below 2% of GDP
- SBP also touched down on improved fiscal discipline as the country posted a primary surplus of 0.6% of GDP during 1Q. However, bloated debt servicing cost has kept the headline deficit number to 1.1% of GDP.

Benchmark interest rates kept steady at 7.0%: In a move that was widely anticipated by the street, the central bank kept benchmark interest rates stable at 7.0%. The central bank shed light on nascent recovery in domestic demand owing to various stimulus packages offered to business in the wake of COVID-19. Consequently, the real GDP is expected to grow by a shade above 2% which is in line with our own growth outlook of 1.9% but significantly higher than IMF's (1%) and World Bank's (1.3%). The risk highlighted in this regard is rebound in COVID-19 cases.

Inflation target maintained between 7% - 9%: Though the headline inflation over the last few months showed more than one out-turns on higher side, the trend is likely to ease off in the coming months owing to several mitigating factors. Firstly, the supply side pressures in food prices are expected to be alleviated as the new crops (of food items like tomatoes) hit the market. Also, the GoP has put in place various administrative measures in order to discourage hoarding of food items such as sugar and wheat which has resulted in a visible correction in prices of these items.

Robust improvement in CAD: Visible improvement in current account balance were observed where 1QFY21 recorded first quarterly surplus in more than five years. Four successive monthly surpluses resulted in a cumulative CAS of USD1.2bn against a deficit of USD1.4bn during SPLY. The turnaround was made possible due to i) a record growth in remittances (up 27%YoY) and ii) improved trade balance as exports gradually recovered to their pre-COVID monthly level of around USD2bn (during September and October); imports meanwhile remained subdued owing to lackluster domestic demand and low global oil prices. Resultantly, with SBP's foreign exchange reserves increased to USD12.9bn, sufficient to cover 3 months of imports.

Investment perspective: Notwithstanding the risks posted to economic activity by a rebound in COVID-19 cases, the local economy is taking nascent steps towards stabilization. Unlike in past, this recovery has been fuelled by improvement in current account which is a step towards sustainable growth. SBP prudently allowed the room for this recovery to continue by keeping rates stable at 7% which will likely be positively received by the market.

Disclaimer

This research report is for information purposes only and does not constitute nor is it intended as an offer or solicitation for the purchase or sale of securities or other financial instruments. Neither the information contained in this research report nor any future information made available with the subject matter contained herein will form the basis of any contract. Information and opinions contained herein have been compiled or arrived at by BIPL Securities Limited from publicly available information and sources that BIPL Securities Limited believed to be reliable. Whilst every care has been taken in preparing this research report, no research analyst, director, officer, employee, agent or adviser of any member of BIPL Securities Limited gives or makes any representation, warranty or undertaking, whether express or implied, and accepts no responsibility or liability as to the reliability, accuracy or completeness of the information set out in this research report. Any responsibility or liability for any information contained herein is expressly disclaimed. All information contained herein is subject to change at any time without notice. No member of BIPL Securities Limited has an obligation to update, modify or amend this research report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. Furthermore, past performance is not indicative of future results.

The investments and strategies discussed herein may not be suitable for all investors or any particular class of investor. Investors should make their own investment decisions using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives when investing. Investors should consult their independent advisors if they have any doubts as to the applicability to their business or investment objectives of the information and the strategies discussed herein. This research report is being furnished to certain persons as permitted by applicable law, and accordingly may not be reproduced or circulated to any other person without the prior written consent of a member of BIPL Securities Limited. This research report may not be relied upon by any retail customers or person to whom this research report may not be provided by law. Unauthorized use or disclosure of this research report is strictly prohibited. Members of BIPL Securities and/or their respective principals, directors, officers, and employees and their families may own, have positions or affect transactions in the securities or financial instruments referred herein or in the investments of any issuers discussed herein, may engage in securities transactions in a manner inconsistent with the research contained in this research report and with respect to securities or financial instruments covered by this research report, may sell to or buy from customers on a principal basis and may serve or act as director, placement agent, advisor or lender, or make a market in, or may have been a manager or a co-manager of the most recent public offering in respect of any investments or issuers of such securities or financial instruments referenced in this research report or may perform any other investment banking or other services for, or solicit investment banking or other business from any company mentioned in this research report. Investing in Pakistan involves a high degree of risk and many persons, physical and legal, may be restricted from dealing in the securities market of Pakistan. Investors should perform their own due diligence before investing. No part of the compensation of the authors of this research report was, is or will be directly or indirectly related to the specific recommendations or views contained in the research report. By accepting this research report, you agree to be bound by the foregoing limitations.

BIPL Securities Limited and / or any of its affiliates, which operate outside Pakistan, do and seek to do business with the company(s) covered in this research document. Investors should consider this research report as only a single factor in making their investment decision. BIPL Securities Limited prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer/company prior to the publication of a research report containing such rating, recommendation or investment thesis.

BIPL Securities Limited endeavors to make all reasonable efforts to disseminate its publication to all eligible clients in a timely manner through either physical or electronic distribution such as mail, fax and/or email. Nevertheless, not all clients may receive the material at the same time.

Disclaimers/Disclosures to US Investors

This investment research is distributed in the United States by BIPL Securities Limited (BIPLS), and in certain instances by Enclave Capital LLC (Enclave), a U.S.-registered broker-dealer, only to major U.S. institutional investors, as defined in Rule 15a-6 promulgated under the U.S. Securities Exchange Act of 1934, as amended, and as interpreted by the staff of the U.S. Securities and Exchange Commission. This investment research is not intended for use by any person or entity that is not a major U.S. institutional investor. If you have received a copy of this research and are not a major U.S. institutional investor, you are instructed not to read, rely on or reproduce the contents hereof, and to destroy this research or return it to BIPLS or to Enclave. The analyst(s) preparing this report are employees of BIPLS who are resident outside the United States and are not associated persons or employees of any U.S. registered broker-dealer. Therefore, the analyst(s) are not subject to Rule 2711 of the Financial Industry Regulatory Authority (FINRA) or to Regulation AC adopted by the U.S. Securities and Exchange Commission (SEC) which among other things, restrict communications with a subject company, public appearances and personal trading in securities by a research analyst. Any major U.S. institutional investor wishing to effect transactions in any securities referred to herein or options thereon should do so by contacting a representative of Enclave. Enclave is a broker-dealer registered with the SEC and a member of FINRA and the Securities Investor Protection Corporation. Its address is 19 West 44th Street, Suite 1700, New York, NY 10036 and its telephone number is 646-454-8600. BIPLS is not affiliated with Enclave or any other U.S. registered broker-dealer.

Stock Rating

Investors should carefully read the definitions of all rating used within every research reports. In addition, research reports carry an analyst's independent view and investors should ensure careful reading of the entire research reports and not infer its contents from the rating ascribed by the analyst. Ratings should not be used or relied upon as investment advice. An investor's decision to buy, hold or sell a stock should depend on said individual's circumstances and other considerations. BIPL Securities Limited uses a three tier rating system: i) Buy, ii) Hold and iii) Sell with our rating being based on total stock returns. A table presenting BIPLS' rating definitions is given below:

The rating system	Rating Definition
Buy	Total stock return \geq 15%
Hold	0% \leq Total stock return < 15%
Sell	Total stock return < 0%

* Total stock return = capital gains + dividend yield

Valuation Methodology

To arrive at our period end target prices, BIPL Securities uses different valuation methodologies including

- Discounted cash flow (DCF, DDM)
- Relative Valuation (P/E, P/B, P/S etc.)
- Equity & Asset return based methodologies (EVA, Residual Income etc.)